12
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Clinical Studies with Liposomal Doxorubicin

, , , &
Pages 481-490 | Published online: 28 Sep 2008
 

Abstract

To present data on a continuing phase I study of liposomal doxorubicin at this time may seem like a giant leap backwards. Liposomally encapsulated doxorubicin has been available for clinical use for some years. Phase I studies have been completed, and phase II studies have been conducted in patients with breast cancer (1,2). Two major obstacles to the commercial exploitation of drugs encapsulated in liposomes were evident. the first was to find a preparation that could be given safely to humans. the second was to develop a pharmaceutical preparation that could be commercially exploited by fulfilling the requirements for manufacture and sale as a drug. the first of these problems was solved a number of years ago, but only recently have we had preparations that fulfilled the second requirement. Two of these have entered clinical trials at Roswell Park Memorial Institute (RPMI). One of these, the liposomally encapsulated muramyl tripeptide derivative (MTP-PE), has been presented previously (3,4). Accordingly, in this paper we will focus on our studies of liposomally encapsulated doxorubicin.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.